US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Quasi-New Stocks

693.11

+3.530.51%

Number of Gainers:82

Number of Losers:60

Number of Flat:12

PE:- -

High:698.59

Open:690.16

Low:683.51

Close:689.59

Volume:81.95M

Turnover:2.49B

Market Cap:484.34B

Float Cap:367.42B

Loading ...

CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy

THOMSON REUTERS

Erasca Says FDA Grants Fast-Track Status to ERAS-0015 for Metastatic Pancreatic Cancer

Edgewise Says Phase 2 Cirrus-HCM Trial Shows Positive Top-Line Data for EDG-7500 in Hypertrophic Cardiomyopathy

Erasca, - Plans Three Potentially Registration-Enabling Trials for Eras-0015 in Pancreatic and Lung Cancers

THOMSON REUTERS

Erasca, - Additional Phase 1 Data for Eras-0015 Expected in H1 2027

THOMSON REUTERS

Erasca Granted FDA Fast Track Designation for Pan-Ras Molecular Glue Eras-0015 in Patients with Metastatic Pancreatic Adenocarcinoma

THOMSON REUTERS

BioXcel Therapeutics Amends Credit Agreement, Extends Financing Deadline

Analysts Offer Insights on Healthcare Companies: Enovis (ENOV) and Aveanna Healthcare Holdings (AVAH)

How Deeper Shopify AXON Integration At AppLovin (APP) Has Changed Its Investment Story

Simply Wall St.

Analysts Offer Insights on Healthcare Companies: Eloxx Pharmaceuticals (ELOX), Cingulate Inc (CING) and Agilon Health (AGL)

Alkami price target raised to $25 from $22 at Needham

Biomea Fusion completes enrollment in COVALENT-211 trial

3 Stocks Estimated To Be Trading Below Intrinsic Value By 37.9% To 46.8%

Simply Wall St.

Needham Adjusts Price Target on Robinhood Markets to $123 From $120

MT Newswires Live

Needham Adjusts Price Target on Coinbase Global to $200 From $177

MT Newswires Live

Monte Rosa Doses First Patient in Phase 2 MODeFIRe-1 Trial of MRT-2359 Plus Apalutamide in mCRPC

Monte Rosa Therapeutics Announces First Patient Dosed in Modefire-1, a Phase 2 Study of Mrt-2359 in Combination with Apalutamide in Patients with Ar Mutation-Positive Metastatic Castration-Resistant Prostate Cancer

THOMSON REUTERS

Monte Rosa Therapeutics - to Provide Phase 1/2 Study Update on Mrt-2359 Plus Enzalutamide by Year-End

THOMSON REUTERS

Biomea Fusion, - Topline 26-Week Primary Endpoint Data from Covalent-211 Expected in Q1 2027

THOMSON REUTERS

Biomea Fusion Announces Completion of Enrollment in Covalent-211 Phase Ii Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/BK4539/news?page=29"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4539","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4539\",,,,,undefined,":{"symbol":"BK4539","market":"US","secType":"PLATE","nameCN":"Quasi-New Stocks","latestPrice":693.1209,"timestamp":1788362184868,"preClose":689.5945,"halted":0,"volume":81942642,"delay":0,"changeRate":0.005114,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":3.526428,"latestTime":"09-02 11:16:24 EDT","open":690.1558,"high":698.5918,"low":683.50885,"amount":2494555831.073843,"amplitude":0.021872,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788379200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.432153,"peRate":146.268293,"turnoverRate":0.006331,"increases":84,"decrements":61,"flats":6,"marketCap":484344284802.125,"floatMarketCap":367423532336},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4539\",,,,,undefined,":{"symbol":"BK4539","high":698.5918,"amplitude":0.021872,"preClose":689.5945,"low":683.50885,"pbRate":"5.432153","latestPrice":693.1133,"volume":81946971,"delay":0,"open":690.1558,"prevYearClose":881.5255,"prevWeekClose":700.4571,"prevMonthClose":701.0681,"prevQuarterClose":742.922,"fiveDayClose":702.0903,"twentyDayClose":709.6846,"sixtyDayClose":720.5922,"secType":"PLATE","market":"US","turnoverRate":0.006331,"peRate":146.268293,"marketCap":484344284802.125,"floatMarketCap":367423532336,"timestamp":1788362185657,"nameCN":"Quasi-New Stocks"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4539\",,,,undefined,":{"bkCode":"BK4539","up":82,"down":60,"flat":12},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4539\",pageSize:20,pageCount:29,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2661276799","title":"CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2661276799","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661276799?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:30","pubTimestamp":1787574600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUA9ZG5KY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CVRX","BK4539","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661276304","title":"Erasca Says FDA Grants Fast-Track Status to ERAS-0015 for Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2661276304","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661276304?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:03","pubTimestamp":1787572997,"startTime":"0","endTime":"0","summary":"Erasca says FDA grants fast-track status to ERAS-0015 for metastatic pancreatic cancerErasca secured FDA Fast Track status for ERAS-0015 to treat metastatic pancreatic adenocarcinoma, accelerating its","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL14y9vR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00BN0W2V16.EUR","LU0314104364.USD","IE00BQXX3C00.GBP","BK4585","BK4539","BK4139","LU2210149790.SGD","LU2095319765.USD","IE00BKPKM429.USD","BCDF","IE00B3QW5Z07.USD","IE00BQXX3F31.USD","SG9999014005.SGD","BK4112","SG9999014039.USD","SG9999014021.USD","LU2210150020.SGD","ERAS","SG9999014013.SGD","NDAQ","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","IE00BQXX3D17.EUR","BK4588","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661276378","title":"Edgewise Says Phase 2 Cirrus-HCM Trial Shows Positive Top-Line Data for EDG-7500 in Hypertrophic Cardiomyopathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2661276378","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661276378?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:02","pubTimestamp":1787572938,"startTime":"0","endTime":"0","summary":"Edgewise says Phase 2 CIRRUS-HCM trial shows positive top-line data for EDG-7500 in hypertrophic cardiomyopathyEdgewise Therapeutics flagged positive top-line results from its 12-week Phase 2 CIRRUS-H","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL5MQ07j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWTX","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661827633","title":"Erasca, - Plans Three Potentially Registration-Enabling Trials for Eras-0015 in Pancreatic and Lung Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2661827633","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661827633?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:00","pubTimestamp":1787572800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUA40QQ31:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ERAS","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661763892","title":"Erasca, - Additional Phase 1 Data for Eras-0015 Expected in H1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2661763892","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661763892?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:00","pubTimestamp":1787572800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUA40QQ31:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","ERAS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661276849","title":"Erasca Granted FDA Fast Track Designation for Pan-Ras Molecular Glue Eras-0015 in Patients with Metastatic Pancreatic Adenocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2661276849","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661276849?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:00","pubTimestamp":1787572800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUA40QQ31:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","ERAS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661276563","title":"BioXcel Therapeutics Amends Credit Agreement, Extends Financing Deadline","url":"https://stock-news.laohu8.com/highlight/detail?id=2661276563","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661276563?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:49","pubTimestamp":1787572174,"startTime":"0","endTime":"0","summary":"Bioxcel Therapeutics ( ($BTAI) ) has shared an announcement. On August 21, 2026, BioXcel Therapeutics entered into a Thirteenth Amendment to its ex...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bioxcel-therapeutics-amends-credit-agreement-extends-financing-deadline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bioxcel-therapeutics-amends-credit-agreement-extends-financing-deadline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661275904","title":"Analysts Offer Insights on Healthcare Companies: Enovis (ENOV) and Aveanna Healthcare Holdings (AVAH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2661275904","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661275904?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:40","pubTimestamp":1787571627,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Enovis (ENOV) and Aveanna Healthcare Holdings (AVA...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-enovis-enov-and-aveanna-healthcare-holdings-avah-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-enovis-enov-and-aveanna-healthcare-holdings-avah-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B19Z6F94.USD","XBI","XLV","BK4082","ENOV","LABU","BK4539","LU2065732104.USD","BK4588","AVAH","BK4196","BK4581","IE0034390439.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661743342","title":"How Deeper Shopify AXON Integration At AppLovin (APP) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2661743342","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661743342?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:25","pubTimestamp":1787570741,"startTime":"0","endTime":"0","summary":"In recent days, AppLovin detailed a deeper integration of its AXON advertising platform within Shopify’s commerce ecosystem, aiming to use merchant and shopper data to improve how ads are targeted and measured across its network.\nThis closed-loop approach, combining Shopify commerce signals with AppLovin’s machine learning and owned ad supply, could meaningfully distinguish its offering from rivals in performance-focused digital advertising.\nNext, we’ll examine how this expanded Shopify-AXON...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/media/nasdaq-app/applovin/news/how-deeper-shopify-axon-integration-at-applovin-app-has-chan","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/media/nasdaq-app/applovin/news/how-deeper-shopify-axon-integration-at-applovin-app-has-chan","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2063271972.USD","LU0056508442.USD","LU1861215975.USD","LU2360106780.USD","LU2087625088.SGD","BK4588","IE00B894F039.SGD","BK4585","IE00B19Z9P08.USD","BK4539","IE00B19Z9Z06.USD","BK4608","CLOD","LU1852331112.SGD","LU0353189680.USD","LU2250418816.HKD","LU2360107168.USD","XDAT","APP","IE00BZ9MQY76.HKD","LU0097036916.USD","LU2290526834.HKD","BK4023","APPX","BK4009","LU0353189763.USD","LU0154236417.USD","BK4613","LU1861220033.SGD","APPC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661275889","title":"Analysts Offer Insights on Healthcare Companies: Eloxx Pharmaceuticals (ELOX), Cingulate Inc (CING) and Agilon Health (AGL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2661275889","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661275889?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:20","pubTimestamp":1787570417,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Eloxx Pharmaceuticals (ELOX), Cingulate Inc (CING) and Agilon Hea...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-eloxx-pharmaceuticals-elox-cingulate-inc-cing-and-agilon-health-agl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-eloxx-pharmaceuticals-elox-cingulate-inc-cing-and-agilon-health-agl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4585","BK4588","BK4196","CING","BK4581","LU0128526141.USD","LU0029874061.USD","XBI","BK4137","LABU","AGL","ELOX","BK4007","XLV","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661027309","title":"Alkami price target raised to $25 from $22 at Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2661027309","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661027309?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:15","pubTimestamp":1787570144,"startTime":"0","endTime":"0","summary":"Needham raised the firm’s price target on Alkami (ALKT) to $25 from $22 and keeps a Buy rating on the shares after hosting meetings with its manage...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alkami-price-target-raised-to-25-from-22-at-needham-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alkami-price-target-raised-to-25-from-22-at-needham-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALKT","BK4023","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661275857","title":"Biomea Fusion completes enrollment in COVALENT-211 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2661275857","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661275857?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:15","pubTimestamp":1787570122,"startTime":"0","endTime":"0","summary":"Biomea Fusion (BMEA) announced the completion of enrollment in COVALENT-211, a randomized, double-blinded, placebo-controlled Phase II clinical tri...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biomea-fusion-completes-enrollment-in-covalent-211-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biomea-fusion-completes-enrollment-in-covalent-211-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BMEA","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661271416","title":"3 Stocks Estimated To Be Trading Below Intrinsic Value By 37.9% To 46.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661271416","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661271416?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:07","pubTimestamp":1787569677,"startTime":"0","endTime":"0","summary":"Over the last 7 days, the United States market has experienced a slight decline of 1.2%, yet it remains up by 18% over the past year with earnings expected to grow by 17% annually. In this context, identifying stocks that are trading below their intrinsic value can be a strategic approach for investors looking to capitalize on potential long-term growth opportunities.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/1033000-choice1-main-header/1585186680256","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/1033000-choice1-main-header/1585186680256"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/energy/nyse-cvi/cvr-energy/news/3-stocks-estimated-to-be-trading-below-intrinsic-value-by-37","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/energy/nyse-cvi/cvr-energy/news/3-stocks-estimated-to-be-trading-below-intrinsic-value-by-37","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4106","BK4563","BK4585","BK4138","BK4094","BK4588","DLO","VSXY","CVI","BK4539","BK4227"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661827398","title":"Needham Adjusts Price Target on Robinhood Markets to $123 From $120","url":"https://stock-news.laohu8.com/highlight/detail?id=2661827398","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661827398?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:04","pubTimestamp":1787569496,"startTime":"0","endTime":"0","summary":"Robinhood Markets (HOOD) has an average rating of overweight and mean price target of $124.65, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CRPT","BLCK","HOOC","HOII","BPAY","IAI","HOOZ","HODU","HOOX","HOOW","HOOY","HOOD","HOOG","FINX","LU1861559042.SGD","BK4539","BK4127","HOYY","LU1861558580.USD","BK4547","HOOI","ROBN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661273604","title":"Needham Adjusts Price Target on Coinbase Global to $200 From $177","url":"https://stock-news.laohu8.com/highlight/detail?id=2661273604","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661273604?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:04","pubTimestamp":1787569493,"startTime":"0","endTime":"0","summary":"Coinbase Global (COIN) has an average rating of overweight and mean price target of $194, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["COIA","ICOI","COIX","LU1861220207.SGD","COYY","BKCH","LU1861217088.USD","FINX","CONL","COIO","BK4595","LU2360107671.USD","CONY","IBLC","BK4516","BK4596","CONI","BK4539","COIN","BLCK","BK4535","BK4112","BK4600","COIG","BK4554","BK4588","CONX","CRPT","BK4585","BK4551","LU1861559042.SGD","FDIG","COII","BITQ","COIW","LU1861558580.USD","FIAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661517273","title":"Monte Rosa Doses First Patient in Phase 2 MODeFIRe-1 Trial of MRT-2359 Plus Apalutamide in mCRPC","url":"https://stock-news.laohu8.com/highlight/detail?id=2661517273","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661517273?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:02","pubTimestamp":1787569332,"startTime":"0","endTime":"0","summary":"Monte Rosa doses first patient in Phase 2 MODeFIRe-1 trial of MRT-2359 plus apalutamide in mCRPCMonte Rosa Therapeutics dosed the first patient in MODeFIRe-1, a Phase 2 trial of MRT-2359 with apalutam","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL4FK4J5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BN0W2W23.USD","IE00BQXX3D17.EUR","BK4588","LU2210150020.SGD","SG9999014005.SGD","IE00BN0W2V16.EUR","BK4112","BK4139","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","LU0314104364.USD","NDAQ","IE00B3QW5Z07.USD","SG9999014039.USD","BK4585","SG9999014013.SGD","SG9999014021.USD","IE00BKPKM429.USD","LU2095319765.USD","BK4539","IE00BQXX3C00.GBP","IE00BQXX3F31.USD","GLUE","LU2210149790.SGD","BCDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661273874","title":"Monte Rosa Therapeutics Announces First Patient Dosed in Modefire-1, a Phase 2 Study of Mrt-2359 in Combination with Apalutamide in Patients with Ar Mutation-Positive Metastatic Castration-Resistant Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2661273874","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661273874?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:00","pubTimestamp":1787569201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUA1XLBHX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","GLUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661273674","title":"Monte Rosa Therapeutics - to Provide Phase 1/2 Study Update on Mrt-2359 Plus Enzalutamide by Year-End","url":"https://stock-news.laohu8.com/highlight/detail?id=2661273674","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661273674?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:00","pubTimestamp":1787569201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUA1XLBHX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GLUE","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661733312","title":"Biomea Fusion, - Topline 26-Week Primary Endpoint Data from Covalent-211 Expected in Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2661733312","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661733312?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:00","pubTimestamp":1787569201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUA4VMQST:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BMEA","BK4139","BK4585","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661361273","title":"Biomea Fusion Announces Completion of Enrollment in Covalent-211 Phase Ii Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=2661361273","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661361273?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:00","pubTimestamp":1787569201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUA4VMQST:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4139","BK4539","BMEA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":42,"pageCount":29,"totalSize":838,"code":"91000000","status":"200"}]}}